Results 161 to 170 of about 5,080 (193)

Lecanemab

Reactions Weekly
  +9 more sources

Lecanemab (Leqembi) for Alzheimer's Disease

The Medical Letter on Drugs and Therapeutics, 2023
Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated ...
openaire   +2 more sources

The unsafe profile of lecanemab

Journal of Alzheimer’s Disease
Lack of data from the US Food and Drug Administration (FDA) Adverse Event System makes analyses of the risks of newly approved anti-Alzheimer's antibodies inadequate to determine whether such risks justify the minimal clinical benefits reported.
Poul F Høilund-Carlsen, Thomas J Werner, Abass Alavi   +2 more
openaire   +3 more sources

Lecanemab Questions

Neurology
The recently published results of the 18-month randomized controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. However, there are a number of matters that deserve further consideration.
openaire   +2 more sources

Evidence for lecanemab in early Alzheimer’s disease

Drug and Therapeutics Bulletin, 2023
Abstract Overview of: van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med.
openaire   +2 more sources

Lecanemab for Alzheimer's Disease

Qapsule: Queen's Undergraduate Health Sciences Journal
Lecanemab is a novel drug developed by Sisai and Biogen aimed at treating Alzheimer’s Disease. Alzheimer’s Disease is characterized by the misfolding and accumulation of neurotoxic amyloid-beta plaques in the brain, leading to neuronal cell death and brain shrinkage.
Bohan Zhu, Yasmine Abossi
openaire   +1 more source

Lecanemab-irmb

American Journal of Health-System Pharmacy, 2023
openaire   +2 more sources

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Neurotherapeutics, 2022
Lars Lannfelt, Malin Johannesson, Christer Möller   +2 more
exaly  

Approval: Lecanemab

The Brown University Psychopharmacology Update, 2023
openaire   +1 more source

Lecanemab: Shared Decision Making

Journal of Gerontological Nursing, 2023
openaire   +2 more sources